^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Telomerase inhibitor

    Related drugs:
    2d
    Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Rytelo (imetelstat)
    3d
    Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=27, Recruiting, Weill Medical College of Cornell University | Trial completion date: Apr 2028 --> Apr 2030 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Telomelysin (suratadenoturev)
    6d
    A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
    P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    RAS mutation • CBL mutation
    |
    cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
    13d
    GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
    GV1001 administered alone or in combination with cisplatin produced antitumor effects. Collectively, these findings demonstrate that GV1001 functions as a potent immunomodulatory anticancer peptide that downregulates CD47 expression and restores macrophage-mediated tumor clearance, highlighting its potential as a therapeutic strategy for OSCC.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • CD47 (CD47 Molecule)
    |
    cisplatin • LucaVax (tertomotide)
    26d
    QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=150, Recruiting, Quetzal Therapeutics
    New P3 trial
    |
    PML (Promyelocytic Leukemia)
    |
    Chr t(15;17)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    30d
    P53-armed Oncolytic Adenovirus Enhances the Efficacy of PD-1 Blockade in Neuroblastoma by Inducing Immunogenic Cell Death. (PubMed, Anticancer Res)
    OBP-702 is a promising antitumor strategy to promote the antitumor effect of ICIs by inducing ICD against NB tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • HMGB1 (High Mobility Group Box 1)
    |
    PD-L1 expression • MYCN amplification
    |
    Telomelysin (suratadenoturev) • pfifteloxin (OBP-702)
    2ms
    HARNESS-1: A Study of the Safety, Pharmacokinetics and Exploratory Efficacy ofnRC220 in Combination with Osimertinib in Adult Patients with Non-nSmall Cell Lung Cancer. (ACTRN12626000325303)
    P1, N=40, Not yet recruiting, Racura Oncology Ltd.
    New P1 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Zantrene (bisantrene)
    2ms
    THIO and Cadonilimab in Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, University of Texas Southwestern Medical Center
    New P1 trial
    |
    Kaitanni (cadonilimab) • ateganosine (THIO)
    2ms
    HSP90 inhibition disrupts telomere maintenance and promotes chromosomal instability (CIN) in cancer cells. (PubMed, Res Sq)
    Methods Four HSP90 inhibitors (TAS-116, XL-888, SNX-2112, 17-AAG) were tested at each compound's cell-specific LC50 in HT1080 (linear and circular HACs) and HEK293 (linear HAC) cells, with GRN163L as a positive control. Conclusions TAS-116 consistently disrupts telomere maintenance-driving linear HAC loss, telomere shortening, reduced FISH signal, elevated TIFs, and increased MNi-thereby validating the HAC-based framework for discriminating telomere-directed activity. These findings support the therapeutic promise of HSP90 inhibition against telomere maintenance in cancer.
    Journal
    |
    HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • TERF2 (Telomeric Repeat Binding Factor 2)
    |
    Jeselhy (pimitespib) • Rytelo (imetelstat) • SNX-2112
    2ms
    GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Samsung Pharmaceutical Co., Ltd. | Trial completion date: Jun 2028 --> Jul 2031
    Trial completion date
    |
    LucaVax (tertomotide)
    2ms
    Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702). (PubMed, Int J Clin Oncol)
    Of these agents, Telomelysin (OBP-301, Suratadenoturev), a telomerase-specific oncolytic adenovirus, demonstrated clinical safety but limited efficacy in refractory tumors. Given its multifaceted antitumor functions and ability to overcome key barriers in pancreatic cancer, OBP-702 represents a highly promising therapeutic candidate. A first-in-human clinical trial evaluating endoscopic ultrasonography-guided intratumoral injection of OBP-702 is currently in preparation, expected to advance clinical translation of this novel virotherapeutic strategy.
    Review • Journal • Tumor mutational burden • IO biomarker • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • E2F1 (E2F transcription factor 1)
    |
    TMB-L
    |
    Telomelysin (suratadenoturev) • pfifteloxin (OBP-702)
    2ms
    Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Jun 2029
    Trial completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)